Large clinical trials [22-24] in patients with chronic kidney disease showed an increase of thromboembolic events due to long-term Epo treatment, and short-term Epo treatment increased platelet count as well as platelet activation in animal models [25-28] and also in healthy human volunteers [29]. Here, EPO is linked to chronic kidney disease.